Yes, lemborexant can be increased from 5 mg to 10 mg in this patient
In a 71-year-old patient who has not responded adequately to lemborexant 5 mg, dose escalation to 10 mg is appropriate and supported by both FDA labeling and clinical trial evidence. Both doses are FDA-approved, and the 10 mg dose has demonstrated superior efficacy compared to 5 mg across multiple sleep parameters without clinically significant safety concerns in older adults 1, 2.
Efficacy Evidence Supporting Dose Escalation
The clinical trial data clearly demonstrates dose-dependent improvements:
- Sleep onset: Lemborexant 10 mg reduced latency to persistent sleep more than 5 mg (geometric mean ratio vs placebo: 0.72 for 10 mg vs 0.77 for 5 mg) 2
- Sleep maintenance: Wake after sleep onset improved by -25.4 minutes with 10 mg compared to -24.0 minutes with 5 mg 2
- Sleep efficiency: Increased by 8.0% with 10 mg versus 7.1% with 5 mg 2
A systematic review of 1,976 patients confirmed these dose-dependent patterns, showing that while both doses are effective, 10 mg consistently produces numerically greater improvements across all sleep parameters 3.
Safety Considerations in Older Adults
The safety profile remains favorable at 10 mg in elderly patients, which is critical for your 71-year-old patient:
- No postural instability: Unlike zolpidem, lemborexant 10 mg did not impair postural stability when awakened in the middle of the night or upon morning awakening 4
- Preserved awakening ability: The 10 mg dose did not affect auditory awakening threshold, meaning patients can still respond to important stimuli (alarms, emergencies) 4
- Minimal cognitive impairment: Morning cognitive performance was not significantly different from placebo 5, 4
The most common adverse event is somnolence, which occurs more frequently than placebo but is generally mild to moderate 2, 3. In clinical trials of older adults (≥55 years), serious adverse events were rare and not treatment-related 2.
Important Caveats
Avoid the 10 mg dose if your patient is taking moderate CYP3A4 inhibitors (e.g., fluconazole, diltiazem, verapamil), as these increase lemborexant exposure by approximately 4-fold 1. In such cases, the maximum dose should be 5 mg.
For patients with hepatic impairment: The 10 mg dose is contraindicated in moderate hepatic impairment (Child-Pugh B), and the maximum dose for severe impairment should be limited to 5 mg 6.
Practical Implementation
- Increase directly to 10 mg at bedtime
- No titration period is necessary
- Reassess efficacy after 1-2 weeks of the higher dose
- Monitor for excessive daytime somnolence, particularly in the first few days
- Ensure the patient is not taking interacting medications (particularly CYP3A4 inhibitors)
The evidence strongly supports that if 5 mg is ineffective, escalation to 10 mg is the appropriate next step, with a favorable risk-benefit profile specifically demonstrated in older adults 2, 5.